Literature DB >> 2400987

T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.

M L Graham1, N L Krett, L A Miller, K K Leslie, D F Gordon, W M Wood, L L Wei, K B Horwitz.   

Abstract

We postulate that one mechanism for the progression of breast cancers to hormone resistance involves the acquisition of mutant estrogen receptors (ER)4 by genetically unstable cell subpopulations. The T47D human breast cancer cell line may be a model for such progression, having sublines that are ER positive and estrogen responsive, ER positive and estrogen resistant, or ER negative. Also, T47D cells can be either hyperdiploid (HD) or hypertetraploid (HT) or persistently alternate between these states. T47DCO cells are a HD and ER-positive, but estrogen-resistant, subline of T47D cells that undergoes spontaneous tetraploidization. Such a stable variant, designated T47Dv, is 85% HT (Cancer Res., 49: 3943, 1989). We now show that single-cell clones derived from the mixed HD/HT T47Dv can be either HD or HT, and can be either estrogen responsive or estrogen resistant, for growth and for progesterone receptor regulation. To begin the study of ER in this model system of T47DCO and their derivatives, we have generated complementary DNA libraries from the parental HD T47DCO cells and have isolated three ER complementary DNA mutants. These include two frame-shift/termination mutants that would encode ERs truncated in the DNA-binding domain and in the hormone-binding domain and a third mutant with a large in-frame deletion spanning the hinge region and a part of the hormone-binding domain. If expressed, these mutant ERs would lack hormone-binding capacity and would be undetected by the anti-ER antibodies currently in clinical use. Genetic instability, when associated with mutant ERs in subpopulations of breast tumor cells, may provide the selective pressure leading to hormone resistance. T47DCO cells and their clonal derivatives provide a model for the systematic study of ER mutations and other mechanisms of hormone resistance in Stage IV breast cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400987

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.

Authors:  E A Musgrove; C S Lee; R L Sutherland
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

2.  BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.

Authors:  Shyam Nathan; Yongxian Ma; York A Tomita; Eliseu De Oliveira; Milton L Brown; Eliot M Rosen
Journal:  Breast Cancer Res Treat       Date:  2017-08-14       Impact factor: 4.872

Review 3.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

4.  Tamoxifen aziridine labeling of the estrogen receptor-potential utility in detecting biologically aggressive breast tumors.

Authors:  S Trivedi; M Piccart; C Muquardt; N Gilot; S Hadiy; D Patel; G Leclercq
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 5.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

6.  Glucocorticoids and androgens up-regulate the Zn-alpha 2-glycoprotein messenger RNA in human breast cancer cells.

Authors:  Y S López-Boado; I Díez-Itza; J Tolivia; C López-Otín
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 7.  Mechanisms of hormone resistance in breast cancer.

Authors:  K B Horwitz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Exon skipping gives rise to alternatively spliced forms of the estrogen receptor in breast tumor cells.

Authors:  R J Miksicek; Y Lei; Y Wang
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain.

Authors:  S A Fuqua; D C Allred; R M Elledge; S L Krieg; M G Benedix; Z Nawaz; B W O'Malley; G L Greene; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Steroid hormone receptors in three human gastric cancer cell lines.

Authors:  C W Wu; Y F Chang; T H Yeh; T J Chang; W Y Lui; F K P'Eng; C W Chi
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.